TRAX Stock Forecast & Price Target

First Tracks is well positioned because ANB033 is attacking the underdeveloped CD122/IL-15 pathway with strong preclinical support, Fast Track designation in celiac disease, and a differentiated Phase 1b design that can show both prevention and healing of mucosal damage. The investment case is strengthened by multiple external readthroughs from ARGX, NVS, and TEVA that have de-risked the mechanism, while upcoming topline data in 4Q26, 1Q27, and 3Q27 create a clear catalyst path across CeD and EoE. Additional upside comes from a broader pipeline that includes Rosnilimab’s encouraging Phase IIb RA data and ANB101’s BDCA2 rationale, with estimated peak sales of about $2B for ANB033 in CeD and roughly $5.4B in risk-unadjusted peak global sales across the program.

First Tracks is a clinical-stage biotech with no commercial revenue and a single-segment R&D model, leaving valuation highly dependent on a few pipeline assets rather than diversified cash flows. The outlook is negative because the stated value is concentrated in ANB033 in celiac disease and eosinophilic esophagitis, while ANB101 is assigned ~0/share and technology/partnerships also ~0/share, implying limited upside from the rest of the platform. Added risk comes from trial delays, potential failure in CeD and EoE, unexpected safety issues, competitive readthroughs, and the ongoing need for external financing before the company becomes cash flow positive.